Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN
Decision brief
Answer first · skim in under a minute
This week, the biotech sector saw a wave of regulatory and business development activity: PHG and KMDA won FDA approvals, FULC halted its pociredir program, RMD closed the Noctrix acquisition, and NVS posted positive data in IgAN. We break down what each event means for pharma teams and investors.
Weekly Buzz PHG KMDA Win rounds up five sourced catalysts: Philips Elevate Plus FDA 510(k) clearance, Kamada’s San Antonio plasma center FDA approval, Fulcrum’s pociredir halt after PRC2 malignancy feedback, ResMed’s Noctrix close, and Novartis ALIGN IgAN eGFR slope data—each tied to primary filings or wires.
Contents9 sections
Key Takeaways
- Philips (PHG): FDA 510(k) clearance for Elevate Plus on EPIQ Elite and Affiniti, announced June 2, 2026.
- Kamada (KMDA): FDA approved the San Antonio plasma center (March 26, 2026); planned capacity about 50,000 liters/year; company cites $8–$10 million annual normal-source plasma revenue at full capacity.
- Fulcrum (FULC): Discontinued pociredir in sickle cell disease on June 1, 2026 after FDA PRC2 malignancy-risk feedback; started strategic alternatives review.
- ResMed (RMD): Completed Noctrix Health acquisition on June 1, 2026; Novartis ALIGN showed ~34% slower eGFR decline with Vanrafia vs placebo over 2.5 years (NCT04573478).
What FDA clearances did Philips and Kamada secure?
Philips announced U.S. regulatory clearance of Elevate Plus for its EPIQ Elite and Affiniti ultrasound systems on June 2, 2026, citing CE Mark and FDA 510(k) clearance for AI and automation features meant to standardize routine exams.
Per the June 2, 2026 GlobeNewswire release, the upgrade targets consistency and fewer repeat scans across users facing staffing pressure.
Kamada announced FDA approval of Kamada Plasma’s San Antonio, Texas collection center on March 26, 2026 after a February 2026 on-site inspection. The SEC exhibit 99.1 states the 11,100 square-foot site supports up to 50 donor beds, about 50,000 liters/year at full capacity, and commercial normal source plasma sales, with planned EMA inspection later.
Why did Fulcrum halt pociredir development?
Fulcrum Therapeutics discontinued pociredir for sickle cell disease on June 1, 2026 and began a comprehensive review of strategic alternatives.
According to the company’s June 1, 2026 Form 8-K and accompanying GlobeNewswire release, FDA meeting minutes dated May 28, 2026 reflected malignancy concerns linked to Tazverik (tazemetostat) withdrawal and concluded any PRC2-targeting intervention carries equivalent malignancy risk—leaving no viable regulatory path for further pociredir development.
What did ResMed close with Noctrix Health?
ResMed completed its acquisition of Noctrix Health on June 1, 2026, making Noctrix a wholly owned subsidiary. The deal expands ResMed’s clinical sleep portfolio into restless legs syndrome (RLS) wearables.
ResMed’s June 1, 2026 GlobeNewswire announcement notes the transaction was previously disclosed on the April 30, 2026 Q3 FY26 earnings call. Separate earnings coverage cited about $340 million consideration; that dollar figure is not restated as a new primary claim here beyond the completed close itself.
How did Novartis pace the IgAN field with ALIGN?
Novartis reported final 2.5-year Phase III ALIGN results for Vanrafia (atrasentan) in adults with IgA nephropathy, published in The Lancet and presented at ERA 2026.
Company-reported annualized total eGFR slope was −2.7 vs −4.1 mL/min/1.73 m²/year for placebo (~34% slower decline; p=0.003). ALIGN is registered as NCT04573478. NIDDK estimates roughly 130,000 people in the United States live with IgA nephropathy, framing commercial scale for the class.
- Endpoint frame: 132 weeks on treatment plus 4-week off-treatment follow-up
- Main stratum: biopsy-proven IgAN, proteinuria ≥1 g/day on RAS inhibition
- UPCR at Week 36: −39.5% Vanrafia vs −1.9% placebo (company table)
What remains unproven after these headlines?
Elevate Plus clearance does not by itself prove hospital share gains or reimbursement outcomes. Kamada’s $8–$10 million full-capacity plasma revenue projection is company guidance, not audited sales. Fulcrum’s strategic review outcome is unknown. ResMed’s Noctrix integration timelines and RLS channel economics are not fully disclosed in the close release. ALIGN’s traditional-approval path still depends on FDA review of the final eGFR package.
Related NovaPharma coverage
- AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
- AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
- Fulcrum Therapeutics company profile
- IgA nephropathy disease hub
Frequently Asked Questions
What FDA clearances did PHG and KMDA announce?
Philips (PHG) announced FDA 510(k) clearance for Elevate Plus on EPIQ Elite and Affiniti ultrasound systems on June 2, 2026. Kamada (KMDA) announced FDA approval of its San Antonio plasma collection center on March 26, 2026, clearing commercial normal source plasma sales after a February 2026 inspection.
Why did Fulcrum discontinue pociredir?
On June 1, 2026, Fulcrum Therapeutics said it discontinued pociredir for sickle cell disease after FDA end-of-phase feedback concluded that pharmacological interventions targeting the PRC2 complex carry equivalent malignancy risk, leaving no viable regulatory path forward, and it started a strategic review.
What did ResMed and Novartis report this week?
ResMed completed its acquisition of Noctrix Health on June 1, 2026, expanding into restless legs syndrome wearables. Novartis reported final ALIGN Phase III Vanrafia (atrasentan) results in IgA nephropathy, with about 34% slower annualized eGFR decline versus placebo over 2.5 years (NCT04573478), published in The Lancet.
Primary Sources
- GlobeNewswire: Philips Elevate Plus FDA 510(k) (June 2, 2026)
- SEC: Kamada San Antonio plasma center FDA approval
- SEC 8-K: Fulcrum discontinues pociredir (June 1, 2026)
- GlobeNewswire: ResMed completes Noctrix acquisition
- The Lancet: ALIGN atrasentan final 2.5-year results
- ClinicalTrials.gov: NCT04573478 (ALIGN)
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pociredir.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
